FBXL16 and endometrial carcinoma: Our work revealed that the abnormal expression of FBXL16 in Ishikawa cells led to the inhibition of GSK3β-dependent cyclin D1 degradation and ultimately the promotion of MPA resistance in endometrial carcinoma.